Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results Feb 14, 2023 10:57 HKT | ![Ocumension](http://www.acnnewswire.com/images/toppage/OcuMension.68.jpg) |
|
医思健康与保诚香港达成战略合作 Feb 13, 2023 19:11 HKT | ![EC](http://www.acnnewswire.com/images/toppage/ECHealthcare68.jpg) |
|
醫思健康與保誠香港達成戰略合作 Feb 13, 2023 19:10 HKT | ![EC](http://www.acnnewswire.com/images/toppage/ECHealthcare68.jpg) |
|
EC Healthcare Announced Strategic Alliance with Prudential Feb 13, 2023 19:09 HKT | ![EC](http://www.acnnewswire.com/images/toppage/ECHealthcare68.jpg) |
|
Novotech 全球报告:亚太地区稳健的 1 期试验增长 Feb 13, 2023 06:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
Novotech 全球報告:亞太地區穩健的 1 期試驗增長 Feb 13, 2023 06:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
노보텍 글로벌 보고서: 아시아 태평양 지역에서 1단계 임상시험의 확고한 성장 Feb 13, 2023 06:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases Feb 10, 2023 21:06 HKT | ![Essex](http://www.acnnewswire.com/images/toppage/Essexbio.68.jpg) |
|
亿胜生物宣布贝伐珠单抗眼科适应症国际多中心III期临床研究完成美国首例患者给药 Feb 10, 2023 20:39 HKT | ![Essex](http://www.acnnewswire.com/images/toppage/Essexbio.68.jpg) |
|
億勝生物宣佈貝伐珠單抗眼科適應症國際多中心III期臨床研究完成美國首例患者給藥 Feb 10, 2023 20:38 HKT | ![Essex](http://www.acnnewswire.com/images/toppage/Essexbio.68.jpg) |
|
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific Feb 10, 2023 19:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
基石药业(02616.HK)百亿估值修复 中长线可期 Feb 09, 2023 10:27 HKT | |
|
基石藥業(02616.HK)百億估值修復 中長線可期 Feb 09, 2023 10:26 HKT | |
|
亚太地区细胞与基因研究:Novotech 的增长速度比世界其它地区快 50% Feb 04, 2023 07:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
亞太地區細胞與基因研究:Novotech 的增長速度比世界其它地區快 50% Feb 04, 2023 07:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
아시아 태평양 지역 세포유전자 연구: 노보텍이 세계의 나머지 모든 기관들보다 50% 더 빠르게 성장 Feb 04, 2023 07:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW Feb 03, 2023 13:00 HKT | ![Novotech](http://www.acnnewswire.com/images/toppage/Novotech.64.jpg) |
|
欧康维视研发的治疗干眼症的I类新药OT-202 I期临床试验完成 Feb 03, 2023 10:03 HKT | ![Ocumension](http://www.acnnewswire.com/images/toppage/OcuMension.68.jpg) |
|
歐康維視研發的治療乾眼症的I類新藥OT-202 I期臨床試驗完成 Feb 03, 2023 10:02 HKT | ![Ocumension](http://www.acnnewswire.com/images/toppage/OcuMension.68.jpg) |
|
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202 Feb 03, 2023 10:01 HKT | ![Ocumension](http://www.acnnewswire.com/images/toppage/OcuMension.68.jpg) |
|